Scirica BM, Braunwald E, Bhatt DL. Saxagliptin, alogliptin, and cardiovascular outcomes. N Engl J Med. 2014;370:483 484. doi: 10.1056/NEJMc1313880. 174. Monami M, Dicembrini I, Mannucci E. Dipeptidyl peptidase-4 in- hibitors and heart failure: a meta-analysis of randomized clini- cal trials. Nutr Metab Cardiovasc Dis. 2014;24:689 697. doi: 10.1016/j.numecd.2014.01.017. 175. Nichols GA, Gullion CM, Koro CE, Ephross SA, Brown JB. The in- cidence of congestive heart failure in type 2 diabetes: an update. Diabetes Care. 2004;27:1879 1884. 176. Pocock SJ, Wang D, Pfeffer MA, Yusuf S, McMurray JJ, Swedberg KB, Ostergren J, Michelson EL, Pieper KS, Granger CB. Predictors of mortality and morbidity in patients with chron- ic heart failure. Eur Heart J. 2006;27:65 75. doi: 10.1093/ eurheartj/ehi555. 177. Smooke S, Horwich TB, Fonarow GC. Insulin-treated diabetes is associated with a marked increase in mortality in patients with advanced heart failure. Am Heart J. 2005;149:168 174. doi: 10.1016/j.ahj.2004.07.005. 178. ORIGIN Trial Investigators, Gerstein HC, Bosch J, Dagenais GR, D az R, Jung H, Maggioni AP, Pogue J, Probstfield J, Ramachandran A, Riddle MC, Ryd n LE, Yusuf S. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med. 2012;367:319 328. doi: 10.1056/NEJMoa1203858. 179. Scheen AJ, Paquot N. Metabolic effects of SGLT-2 inhibitors beyond increased glucosuria: a review of the clinical evidence. S1262-3636(14)72689-8. 180. Fitchett D, Zinman B, Wanner C, Lachin JM, Hantel S, Salsali A, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE, on behalf of the EMPA-REG OUTCOME trial investigators. Heart failure out- comes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME trial. Eur Heart J. 2016;37:1526 1534. doi: 10.1093/eurheartj/ ehv728. 181. Skyler JS, Bergenstal R, Bonow RO, Buse J, Deedwania P, Gale EA, Howard BV, Kirkman MS, Kosiborod M, Reaven P, Sherwin RS. 